The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...

Thanks to lab-grown miniature intestines, researchers at Uppsala University have successfully mapped how aggressive Shigella bacteria infect the human gut. The study opens the door to using cultured ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

Bharat Biotech has partnered with GSK to develop a Shigellosis vaccine. The altSonflex1-2-3 candidate is one of the most ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International. The U.K. pharma company on Thursday said the agreement paves the way for the development ...